基于质粒的蛋白激酶B1特异性小干扰RNA和P53共表达协同抑制肝细胞癌细胞的增殖、迁移和侵袭

基于质粒的蛋白激酶B1特异性小干扰RNA和P53共表达协同抑制肝细胞癌细胞的增殖、迁移和侵袭

陈小龙万亚锋黄平

解剖学报 ›› 2021, Vol. 52 ›› Issue (2) : 251-257.

PDF(6293 KB)

欢迎访问《解剖学报》官方网站！今天是 English

PDF(6293 KB)

解剖学报 ›› 2021, Vol. 52 ›› Issue (2) : 251-257. DOI: 10.16098/j.issn.0529-1356.2021.02.014

肿瘤生物学

基于质粒的蛋白激酶B1特异性小干扰RNA和P53共表达协同抑制肝细胞癌细胞的增殖、迁移和侵袭

陈小龙¹ 万亚锋²黄平^1*

作者信息 +

Co-expression of plasmid-based protein kinase B1-specific small interfering RNA and P53 synergistically inhibits proliferation, migration and invasion of hepatocellular carcinoma cells

CHEN Xiao-long¹WANG Ya-feng² HUANG Ping^1*

Author information +

文章历史 +

摘要

目的探讨蛋白激酶B1（Akt1）特异性小干扰RNA（siRNA）和p53共表达质粒对肝细胞癌（HCC）细胞增殖、迁移、侵袭、凋亡的影响。方法构建了一种共表达蛋白激酶B1（Akt1）特异性siRNA和野生型p53基因的双表达质粒(pSi-Akt1-P53)。将pSi-Akt1-P53共表达质粒转染至肝癌HepG2细胞，采用Real-time PCR法和免疫印迹法检测细胞中Akt1和P53表达被调控情况。然后将这种共表达质粒转染至HepG2细胞中，并同shAkt1质粒和P53质粒相比较，分别采用CCK-8和5-乙炔基-2’-脱氧尿苷（EdU）实验、划痕实验、Transwell小室法、流式细胞术检测其对HepG2细胞增殖、迁移、侵袭和凋亡的影响。结果 pSi-Akt1-P53共表达质粒转染至肝癌HepG2细胞后显著地减少HepG2细胞中Akt1蛋白的表达，同时显著增加P53蛋白的表达。与shAkt1质粒和P53质粒相比，pSi-Akt1-P53共表达质粒更显著地抑制HepG2细胞的增殖、迁移和侵袭能力，同时更显著地促进HepG2细胞的凋亡。结论 pSi-Akt1-P53共表达质粒能非常显著地抑制肝癌HepG2细胞的增殖、迁移和侵袭能力，有效促进肝癌HepG2细胞凋亡。

Abstract

Objective To investigate the effect of the dual expression plasmid of protein kinase B1(Akt1)-specific siRNA and P53 on the proliferation, migration, invasion and apoptosis of hepatocellular carcinoma (HCC) cells. Methods We constructed a dual expression plasmid that co-expressed Akt1-specific siRNA and wild-type p53 gene (pSi-Akt1-P53).The dual expression plasmid pSi-Akt1-P53 was transfected into HepG2 cells of HCC,The expression of Akt1 and P53 was detected by Real-time PCR and Western blotting. Then, the dual expression plasmid was transfected into HepG2 cells, sh-Akt1 plasmid and P53 plasmid were used as control. The effects of the dual plasmid on the proliferation, migration, invasion and apoptosis of HepG2 cells were detected by CCK-8 and 5-ethynyl-2’-deoxyuridine(EdU) experiments, Wound scratch experiment, Transwell chamber experiment and flow cytometry,respectively. Results After the dual plasmid was transfected into HepG2 cells, the expression of Akt1 protein was significantly reduced and the expression of P53 protein was significantly increased in HepG2 cells. Compared with the shAkt1 and P53 plasmids, the dual expression plasmid pSi-Akt1-P53 significantly inhibited the proliferation、migration and invasion of HepG2 cells and significantly increased the apoptosis of HepG2 cells. Conclusion The dual expression plasmid pSi-Akt1-P53 can synergistically inhibit the proliferation, migration and invasion of HepG2 cells, significantly increased the apoptosis of HepG2 cells.

关键词

肝细胞癌 / 共表达质粒 / 蛋白激酶B1 / P53 / 实时定量聚合酶链反应 / 人

Key words

Hepatocellular carcinoma / Dual expression plasmid / Protein kinase B1 / P53 / Real-time PCR / Human

引用本文

导出引用

陈小龙万亚锋黄平. 基于质粒的蛋白激酶B1特异性小干扰RNA和P53共表达协同抑制肝细胞癌细胞的增殖、迁移和侵袭[J]. 解剖学报. 2021, 52(2): 251-257 https://doi.org/10.16098/j.issn.0529-1356.2021.02.014

CHEN Xiao-long WANG Ya-feng HUANG Ping. Co-expression of plasmid-based protein kinase B1-specific small interfering RNA and P53 synergistically inhibits proliferation, migration and invasion of hepatocellular carcinoma cells[J]. Acta Anatomica Sinica. 2021, 52(2): 251-257 https://doi.org/10.16098/j.issn.0529-1356.2021.02.014

中图分类号： R735.7

参考文献

［1］ Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma ［J］. Lancet, 2003, 362(9399): 1907-1917.

［2］ Yang T, Zhang J, Lu JH, et al. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort ［J］. J Cancer Res Clin Oncol, 2011, 137 (5):739-750.

［3］ Aylon Y, Oren M. Living with p53, dying of p53 ［J］. Cell, 2007, 130(4): 597-602.

［4］ Carmer E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death ［J］. Cell Cycle, 2008, 7(3): 277-282.

［5］ Lin ZhX, Zhang PF, Jiang CZh, et al. The exploration of relationship between immunohistochemistry of LN, FN, p53 and tumorous invasion microecosystem in human brain glioma ［J］. Acta Anatomica Sinica，2002，33(4): 360-365. (in Chinese)

林志雄，张鹏飞，江常震，等. 人脑胶质瘤中LN、FN及p53基因蛋白的免疫组织化学与其侵袭微生态系统的相关性探讨［J］. 解剖学报，2002，33(4): 360-365.

［6］ Soussi T, Ishioka C, Claustres M, et al．Locus-specific mutation databases: pitfalls and good practice based on the p53 experience ［J］. Nat Revi Cancer, 2006, 6(1): 83-90.

［7］ Cancer Genome Atlas Research Network, Electronic address:wheeler@bcm.edu. Comprehensive and integrative genomic characterization of hepatocellular carcinoma ［J］. Cell, 2017, 169(7): 1327-1341.

［8］ Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase Akt pathway in human cancer ［J］. Nat Rev Cancer, 2002, 2(7), 489-501.

［9］ Sheppard K, Kinross KM, Solomon B, et al. Targeting PI3 kinase/Akt/mTOR signaling in cancer ［J］. Crit Rev Oncog, 2012, 17(1): 69-95.

［10］ Kornelius S, Sandrine I, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets ［J］. Nat Genet, 2015, 47(5): 505-511.

［11］ Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/Akt-a major therapeutic target ［J］. Biochim Biophys Acta, 2004, 1697(1-2): 3-16.

［12］ Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer ［J］. Cell cycle, 2009, 8(16): 2502-2508.

［13］ Su JS, Woods SM, Ronen SM. Metabolic consequences of treatment with Akt inhibitor perifosine in breast cancer cells ［J］. NMR Biomed, 2012, 25(2): 379-388.

［14］ Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene ［J］. Genes Dev, 2001, 15(17): 2203-2208.

［15］ Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice ［J］. J Biol Chem, 2001, 276(42): 38349-38352.

［16］ Hartmann W, Digonsontgerath B, Koch A, et al. Phosphatidylinositol 3’-kinase/Akt signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN［J］. Clin Cancer Res, 2006, 12(10): 3019-3027.

［17］ Suzuki Y, Toquenaga Y. Effects of information and group structure on evolution of altruism: analysis of two-score model by Covariance and contextual analyses ［J］. J Theor Bio, 2005, 232(2): 191-201.

［18］ Mottet D, Dumont V, Deceache Y, et al. Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta pathway in HepG2 cells ［J］．J Biol Chem, 2003, 278(33): 31277-31285.

［19］ Liu L, Zhu S, Gong I, et al. K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis ［J］. PLoS One, 2008, 3(8): e2850．

［20］ Hernandez A, lcoceba R, Sangro B, et al. Genetherapy of liver cancer ［J］. Ann Hepatol, 2007, 6(1): 5-14.

［21］ Bourdon JC, Laurenzi VD, Melion G, et al. p53: 25 years of research And more questions to answer ［J］. Cell Death Differ, 2003, 10(4): 397-399.

［22］ Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase Ⅰ study of a systemically delivered p53 nanoparticle in advanced solid tumors ［J］. Mol Ther, 2013, 21(5): 1096-1103.

［23］ Cheson BD. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma ［J］. N Engl J Med, 2014, 370(11): 1008-1018.

［24］ Zhang L, Gao L, Li Y, et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth ［J］. Clin Cancer Res,2008, 14(2): 559-568.

［25］ Wang GM, Ren ZX, Wang PS, et al. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo ［J］. Oncol Rep,2014, 32(2): 573-580.

［26］ Li X, Li Y, Hu J, et al. Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo ［J］. Cancer Lett, 2013, 335(1): 242-250.

PDF(6293 KB)

Accesses

Citation

Detail

段落导航

相关文章

/

〈

〉